Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Postoperative Tumor-Informed Circulating Tumor DNA Status for Molecular Residual Disease Detection After Curative-Intent Resection of Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-Analysis.

Created on 12 Nov 2026

Authors

Wajahat Mirza, Minhaj Rafi, Zubair Siddiqui, Malaika Mehboob, Mohammad Zian Khan, Khadeeja Khan, Muhammad Hashir Ishaq, Muhammad Shalikh, Masoud Altabawi, Abdullah Imtiaz, Rao Nouman Ali

Published in

Journal of gastrointestinal cancer. Volume 57. Issue 1. Nov 11, 2026. Epub Nov 11, 2026.

Abstract

Pancreatic ductal adenocarcinoma (PDAC) frequently recurs after curative-intent resection, and conventional imaging and CA19-9 have limited sensitivity for detecting molecular residual disease (MRD). Tumor-informed circulating tumor DNA (ctDNA) may identify postoperative MRD, although the evidence is limited and heterogeneous.
PubMed, Scopus, and Embase were searched from inception to July 9, 2026, following PRISMA 2020 guidelines. Eligible studies compared postoperative tumor-informed ctDNA-positive and ctDNA-negative patients after curative-intent treatment of pancreatic cancer for recurrence, survival, or lead time outcomes. Random-effects models were used to pool risk ratios (RRs) and hazard ratios (HRs). Heterogeneity, leave-one-out sensitivity, prespecified subgroups, ROBINS-I risk of bias, and GRADE certainty were assessed.
Five observational cohorts contributed 237 patients to the radiological recurrence comparison (84 ctDNA-positive and 153 ctDNA-negative). Postoperative ctDNA positivity was associated with increased radiological recurrence (RR 2.50; 95% CI 1.90-3.28; I²=20%), poorer disease-free survival (HR 8.11; 95% CI 3.51-18.73; I²=45%), and poorer overall survival (HR 5.15; 95% CI 2.67-9.94; I²=0%). The direction of the associations persisted in the reported leave-one-out assessments. Recurrence risk was higher in both the early-MRD/landmark and surveillance subgroups, with no statistically significant subgroup difference (P = 0.17).
Postoperative tumor-informed ctDNA positivity was associated with an increased recurrence risk and inferior survival after curative-intent PDAC treatment, although a negative result did not reliably exclude residual disease. Prospective interventional studies are needed before ctDNA-guided surveillance or treatment modifications can be recommended for routine practice.

PMID:
43013192
Bibliographic data and abstract were imported from PubMed on 12 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 6
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement